BCI invests in Tolerance Bio’s new treatment aiming to retrain the immune system

Beyond Celiac Investments (BCI), the venture philanthropy program of Beyond Celiac, announced an investment in Tolerance Bio Inc. to support advancement of its celiac disease program through early development and preclinical proof of concept. The funding will support Tolerance Bio’s approach to rest…

View Post on Scour ↗

More from longevity.technology on Scour.

Rate this post to improve your feed:
🌰 Love 👍 Like 👎 Not for me